Neuland Laboratories (BOM:524558) Debt-to-Equity : 0.07 (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Neuland Laboratories Debt-to-Equity?

Neuland Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹413 Mil. Neuland Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹541 Mil. Neuland Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹12,827 Mil. Neuland Laboratories's debt to equity for the quarter that ended in Mar. 2024 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neuland Laboratories's Debt-to-Equity or its related term are showing as below:

BOM:524558' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.34 Max: 1.11
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Neuland Laboratories was 1.11. The lowest was 0.07. And the median was 0.34.

BOM:524558's Debt-to-Equity is ranked better than
76.89% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:524558: 0.07

Neuland Laboratories Debt-to-Equity Historical Data

The historical data trend for Neuland Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuland Laboratories Debt-to-Equity Chart

Neuland Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.37

0.23

0.29

0.13

0.07

Neuland Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.13	N/A	0.09	N/A	0.07

Competitive Comparison of Neuland Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuland Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Debt-to-Equity falls into.

Neuland Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neuland Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(412.656	+	541.24)	/	12827.048
	=	0.07

Neuland Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(412.656	+	541.24)	/	12827.048
	=	0.07

Neuland Laboratories (BOM:524558) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neuland Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neuland Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuland Laboratories (BOM:524558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neuland Laboratories Ltd (BOM:524558) » Definitions » Debt-to-Equity

Traded in Other Exchanges

NEULANDLAB:India

Address

Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033

Website

https://www.neulandlabs.com

Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.

Neuland Laboratories (BOM:524558) Headlines

No Headlines